tiprankstipranks

Neurocrine price target lowered to $183 from $191 at JPMorgan

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Ingrezza revenue assumptions, expenses, and share count.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue